Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
Metformin use in Type 2 Diabetes shows inconsistent clinical effects in review
Metformin Does More Than Lower Blood Sugar For Your Health
This review examines metformin in over 150 million individuals worldwide receiving treatment annually for Type 2 Diabetes.
Metformin might be doing much more than just controlling blood sugar for people with diabetes.
Review of observational data links semaglutide and tirzepatide to survival in breast cancer
Semaglutide linked to lower death rates in breast cancer patients compared to other diabetes drugs
This review synthesized observational, propensity-matched analyses of patients with pre-existing breast cancer.
In routine care, semaglutide users with breast cancer had significantly lower death rates and less metastatic disease than those on other co…
Computational model review predicts dual optima for combination therapy in ageing
New math model shows combining drugs could slow aging better than weight loss alone
This review of a computational model explores combination therapy with semaglutide, SGLT2 inhibitors, metformin, and rapamycin for ageing.
A new computer model reveals that fixing blood sugar and slowing aging are separate tasks, meaning some drugs might help you live longer eve…
Meta-analysis finds preadmission metformin use associated with reduced mortality in diabetic sepsis patients
Metformin Linked to Lower Sepsis Death Risk
This systematic review and meta-analysis of 14 studies (12,687 patients) examined preadmission metformin use in diabetic sepsis patients.
Diabetic patients taking metformin before sepsis face nearly 40% lower death risk, suggesting this common pill may quietly boost survival du…
Narrative review explores metformin and trimetazidine in cardiovascular conditions
The Hidden Cell Death Process Quietly Driving Heart Disease
This narrative review examines the roles of metformin and trimetazidine in cardiovascular diseases, atherosclerosis, vascular calcification,…
A specific type of cell death driven by iron and fat damage plays a key role in multiple heart conditions, including heart failure and ather…
Review summarizes fenofibrate, metformin, and MSC modulation in Primary Sjögren disease management
The Dry Mouth Disease Has an Immune Fix Researchers Didn't Expect
This review examines the potential of fenofibrate, metformin, and mesenchymal stem cells in Primary Sjögren disease management.
Three existing drugs may restore the immune balance broken in Sjögren's disease, a chronic condition that destroys saliva and tear glands.
Bayesian network meta-analysis evaluates antidiabetic medications and dementia risk in 4,382,897 patients
Could diabetes drugs lower dementia risk, or raise it for some patients?
This Bayesian network meta-analysis synthesized data from 28 articles involving 4,382,897 patients to assess antidiabetic drugs and dementia…
Insulin and metformin cut dementia risk, but DPP4 inhibitors may double Alzheimer's risk compared to SGLT2 drugs in diabetes patients.
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
Diabetes Meds Do Not Stop COVID-19
A mini-review of observational studies in patients with type 2 diabetes mellitus found that insulin was linked to worse COVID-19 outcomes, w…
Recent research proves that common diabetes pills do not protect you from getting sick or dying from a virus infection.
Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin
A New Diabetes Pill Takes On Ozempic's Oral Cousin
A phase 3 RCT of 1698 adults with type 2 diabetes inadequately controlled on metformin found that once-daily oral orforglipron (12 mg or 36 …
A new once-daily diabetes pill called orforglipron lowered blood sugar better than oral semaglutide in a major head-to-head trial, but at th…
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…